Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270949
Substrate
n/a
Meas. Tech.
ChEMBL_552586 (CHEMBL956458)
pH
7.4±n/a
Kd
13000±n/a nM
Comments
extracted
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270949
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-pyrrol-3-yl)propanamido]-3-phenylpropanamido]-N-methylacetamido}-N-methylacetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL510720
Type:
Small organic molecule
Emp. Form.:
C71H101N17O16S2
Mol. Mass.:
1512.796
SMILES:
CC(C)C[C@H](N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cc[nH]c1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:47.49,18.26,81.83,100.104,wD:62.65,51.61,43.45,75.79,29.37,4.4,96.101,(21.59,-4.94,;22.93,-5.71,;22.93,-7.25,;24.26,-4.94,;24.26,-3.4,;22.93,-2.63,;21.59,-3.4,;22.93,-1.09,;24.26,-.32,;21.59,-.32,;21.59,1.22,;22.93,1.99,;20.26,1.99,;20.26,3.54,;18.93,1.22,;17.59,1.99,;16.26,1.22,;16.26,-.32,;14.92,1.99,;14.92,3.54,;16.26,4.31,;16.26,5.85,;17.59,6.62,;18.93,5.85,;18.93,4.31,;17.59,3.54,;13.59,1.22,;12.26,1.99,;12.26,3.54,;10.92,1.22,;10.92,-.31,;12.25,-1.09,;13.73,-.62,;14.62,-1.88,;13.7,-3.12,;12.24,-2.62,;9.59,1.99,;8.26,1.22,;8.26,-.32,;6.92,1.99,;5.58,1.22,;4.25,1.99,;4.25,3.54,;2.91,1.22,;1.58,1.99,;.25,1.22,;.25,-.32,;-1.09,1.99,;-2.42,1.22,;-3.75,1.99,;-3.75,3.54,;-5.09,1.22,;-5.09,-.32,;-3.75,-1.09,;-2.42,-.32,;-1.09,-1.09,;-1.09,-2.63,;-2.42,-3.4,;-3.75,-2.63,;-6.42,1.99,;-7.76,1.22,;-9.1,1.99,;-7.76,-.32,;-9.1,-1.09,;-6.42,-1.09,;-6.42,-2.63,;-7.76,-3.4,;-7.76,-4.94,;-9.1,-5.71,;-10.43,-4.94,;-9.1,-7.25,;-1.09,3.54,;-1.1,5.08,;.45,3.54,;-2.63,3.52,;2.91,-.32,;1.58,-1.09,;4.25,-1.09,;25.59,-2.63,;25.59,-1.09,;26.93,-3.4,;28.27,-2.63,;28.27,-1.09,;29.6,-.32,;30.94,-1.09,;32.27,-.32,;32.27,1.22,;33.6,1.99,;30.94,1.99,;29.6,1.22,;29.6,-3.4,;30.94,-2.63,;29.6,-4.94,;28.36,-5.85,;28.83,-7.31,;30.37,-7.31,;30.85,-5.85,;32.13,-4.98,;32.09,-3.45,;33.47,-5.73,;34.79,-4.93,;34.77,-3.4,;33.41,-2.65,;36.14,-5.68,;37.46,-4.89,;36.17,-7.22,)|
Structure:
Search PDB for entries with ligand similarity: